We are looking forward to attending PCMA next week and connecting with colleagues, friends and partners. Are you heading to PCMA? Reach out and we can schedule time or look for us all around the conference and say hello! Safe travels and see you in Orlando!!
read full article ›Optum’s new tool, “Specialty Fusion,” is another example of vertically integrated payer unlocking specialty management across pharmacy and medical benefits. Manufacturers beware, solutions like Specialty Fusion will allow payers to leverage the dynamics of managing specialty across multiple benefits, including – competition across benefits to drive to low-net cost therapies, single PA tool, greater efficiency with real-time benefit information for the prescriber, and optimized site of service selection (helping the patient secure the lowest cost site of care).
read full article ›Headed to the Festival of Biologics this March? We hope you will join Real Endpoints President, Susan Raiola and other distinguished panel participants, as they discuss "Promoting Biosimilar Update"
read full article ›Important piece not merely on why companies should be talking with payers about Ph III trials — but specifically what in the trials they should be talking about. Quotes from our colleagues Jane F. Barlow, MD, MPH, MBA and Roger Longman help clarify the discussion.
read full article ›Wyden’s aren’t the only complaints about the accelerated approval program. Payers are increasingly concerned they’re not getting the data they need to evaluate the drugs and will increasingly ask companies with these approvals to risk-share on safety and efficacy. Even mid-size plans are getting into the act (via, for example, RE Marketplace)
read full article ›Come hear us share at the 2022 BIO International Convention, June 13-16, in San Diego, California
read full article ›While payers add and delete drugs from formularies for a variety of reasons (e.g., cost, PB vs MB, generics) patients pay the ultimate price – delays in treatment due to more onerous PA process and/or higher out-of-pocket costs. Notably UHC has excluded Rebif (MS) while CVS removed Aimovig (migraines) and Eliquis (blood thinner).
read full article ›On the front page of Drug Channels Institute today is Real Endpoints CEO, Jeff Berkowitz who introduces Real Endpoints' tech-enabled solution to the Medicare copay problem, RE Assist.
read full article ›Biotech stocks are a mess — but the stock of skilled execs, particularly in Boston, is sky high. And judging from how often we’re asked to suggest market-access candidates, the demand for execs who understand reimbursement is white hot.
read full article ›The Digital Therapeutics Alliance has released an updated guide to the International DTx Regulatory & Reimbursement Pathways for 8 major markets, including the US (which desperately needs to accelerate coverage and adoption of innovative treatments in areas of unmet need).
read full article ›